BL 8040

Drug Profile

BL 8040

Alternative Names: 4F-Benzoyl-TN14003; BKT-140; BL-8040; TF-14016; TN-14003

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Genentech; Merck AG; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Stem cell mobilisation
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stem cell mobilisation
  • Phase II Acute myeloid leukaemia; Pancreatic cancer
  • Phase I/II Aplastic anaemia; Gastric cancer; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer
  • No development reported Autoimmune disorders; Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 18 Jun 2018 Updated efficacy and pharmacodynamics data from a phase IIa trial in Acute myeloid leukaemia presented at the 23rd Annual Congress of the European Hematology Association (EHA-2018)
  • 14 Jun 2018 Adverse events data from a phase II trial in Stem cell mobilisation presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 14 Jun 2018 Interim efficacy and adverse events data from a phase Ib trial in Aplastic anaemia or Myelodysplastic syndromes presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top